Diabetes Mellitus as a Novel Risk Factor for Gastrointestinal Malignancies

References

• . Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol. 2004;159(12):1160–1167
   PubMed Web of Science ®Google Scholar
• . Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035 for the IDF Diabetes Atlas. Diabetes Res Clin Pract. 2014;103(2):137–149
   PubMed Web of Science ®Google Scholar
• . Beagley J, Guariguata L, Weil C, Motala AA. Global estimates of undiagnosed diabetes in adults for 2013 for the IDF Diabetes Atlas. Diabetes Res Clin Pract. 2014;103(2):150–160
   PubMed Web of Science ®Google Scholar
• . Siegel R, Naishadham D, Jemal A. Cancer Statistics, 2013. CA. 2013;63(1):11–30
   Google Scholar
• . Altekruse SF, Henley SJ, Cucinelli JE, McGlynn KA. Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol. 2014;109(4):542–553
   PubMed Web of Science ®Google Scholar
• . Davis DM, Marcet JE, Frattini JC, Prather AD, Mateka JJ, Nfonsam VN. Is it time to lower the recommended screening age for colorectal cancer? J Am Coll Surg. 2011;213(3):352–361
   Google Scholar
• . Ahnen D, Wade S, Jones W,. The increasing incidence of young-onset colorectal cancer: a call to action. Mayo Clin Proc. 2014;89(2):216–224
   PubMed Web of Science ®Google Scholar
• . El-Serag HB. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 2003;139(10):817–823
   PubMed Web of Science ®Google Scholar
• . O'Connor S, Ward J, Watson M, Momin B, Richardson L. Hepatocellular carcinoma—United States, 2001–2006. MMWR. 2010;59(17):517–520
   Google Scholar
• . Chalasani N, Younossi Z, Lavine JE,. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005–2022
   PubMed Web of Science ®Google Scholar
• . Llovet J, Ricci S, Mazzaferro V,. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390
   PubMed Web of Science ®Google Scholar
• . Bugianesi E. Non-alcoholic steatohepatitis and cancer. Clin Liver Dis. 2007;11:197–207
   Google Scholar
• . Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology. 2002;36(6):1349–1354
   PubMed Web of Science ®Google Scholar
• . Marchesini G, Brizi M, Morselli-Labate AM,. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999;107:450–455
   PubMed Web of Science ®Google Scholar
• . Kim CH, Younossi ZM. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med. 2008;75(10):721–728
   PubMed Web of Science ®Google Scholar
• . Dunn W, Wingard DL, Rogers C, Angulo P, Younossi ZM, Schwimmer JB. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol. 2008;103(9):2263–2271
   PubMed Web of Science ®Google Scholar
• . Day CP. Pathogenesis of NASH. Best Pract Res Clin Gastroenterol. 2002;16(5):663–678
   PubMed Web of Science ®Google Scholar
• . Harrison SA. Nonalcoholic steatoheptitis: what we know in the new millennium. Am J Gastroenterol. 2002;97(11):2714–2724
   Google Scholar
• . Szczepaniak LS, Nurenberg P, Leonard D,. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab. 2005;288(2):E462–E468
   PubMed Web of Science ®Google Scholar
• . Bellentani S, Marino M. Epidemiology and natural history of nonalcoholic fatty liver disease (NAFLD). Ann Hepatol. 2009;8( Suppl 1):S4–S8
   PubMed Web of Science ®Google Scholar
• . Browning J, Szczepaniak L, Dobbins R,. Prevalence of hepatic steatosis in an urban population in the united states: impact of ethnicity. Hepatology. 2004;40:1387–1395
   PubMed Web of Science ®Google Scholar
• . Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol. 2006;40( Suppl 1):S5–S10
   PubMed Web of Science ®Google Scholar
• . Jimba S, Nakagami T, Takahashi M,. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med. 2005;22:1141–1145
   PubMed Web of Science ®Google Scholar
• . Wang CS, Yao WJ, Chang TT, Wang ST, Chou P. The impact of type 2 diabetes on the development of hepatocellular carcinoma in different viral hepatitis statuses. Cancer Epidemiol Biomarkers Prev. 2009;18(7):2054–2060
   Google Scholar
• . Donadon V, Balbi M, Ghersetti M,. Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J Gastroenterol. 2009;15(20):2506–2511
   PubMed Web of Science ®Google Scholar
• . Polesel J, Zucchetto A, Montella M,. The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. Ann Oncol. 2009;20(2):353–357
   PubMed Web of Science ®Google Scholar
• . Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut. 2005;54(4):533–539
   PubMed Web of Science ®Google Scholar
• . El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 2004;126(2):460–468
   PubMed Web of Science ®Google Scholar
• . Chiu CC, Huang CC, Chen YC,. Increased risk of gastrointestinal malignancy in patients with diabetes mellitus and correlations with anti-diabetes drugs: a nationwide population-based study in Taiwan. Intern Med. 2013;52:939–946
   PubMed Web of Science ®Google Scholar
• . El Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol. 2006;4(3):369–380
   Google Scholar
• . Luo J, Chlebowski R, Liu S,. Diabetes mellitus as a risk factor for gastrointestinal cancers among postmenopausal women. Cancer Causes Control. 2013;24:577–585
   PubMed Web of Science ®Google Scholar
• . Caldwell S, Argo C, Al-Osaimi A. Therapy of NAFLD. Clin Gastroenterol. 2006;40( Suppl 1):S61–S66
   Google Scholar
• . Furuya CK, deOliveira CP, de Mello ES,. Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years. J Gastroenterol Hepatol. 2007;22(4):510–514
   PubMed Web of Science ®Google Scholar
• . Chavez-Tapia N, Tellez-Avila F, Barrientos-Gutierrez T, Mendez-Sanchez N, Lizardi-Cervera J, Uribe M. Bariatric surgery for nonalcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev. 2010;1:CD007340
   Google Scholar
• . Ueda M, Endo I, Nakashima M,. Prognostic factors after resection of pancreatic cancer. World J Surg. 2009;33:104–110
   PubMed Web of Science ®Google Scholar
• . Conroy T, Desseigne F, Ychou M,. FOLFIRINOX versus Gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–1825
   PubMed Web of Science ®Google Scholar
• . Chari ST, Leibson CL, Rabe KG,. Probability of pancreatic cancer following diabetes: a population based study. Gastroenterology. 2005;129(2):504–511
   PubMed Web of Science ®Google Scholar
• . Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625–1638
   PubMed Web of Science ®Google Scholar
• . Michaud D. Physical activity, obesity, height, and the risk of pancreatic cancer. JAMA. 2001;286(8):921–929
   Web of Science ®Google Scholar
• . Li D, Morris JS, Liu J,. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA. 2009;301(24):2553–2562
   PubMed Web of Science ®Google Scholar
• . Gumbs AA. Obesity, pancreatitis, and pancreatic cancer. Obes Surg. 2008;18(9):1183–1187
   Google Scholar
• . Everhart J, Wright D. Diabetes Mellitus as a risk factor for pancreatic cancer. A meta analysis. JAMA. 1995;273(20):1605–1609
   PubMed Web of Science ®Google Scholar
• . Huxley R, Ansary-Moghaddam A, Gonzalez ABd, Barzi F, Woodward M. Type II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer. 2005;92(11):2076–2083
   PubMed Web of Science ®Google Scholar
• . Pannala R. Temporal association of changes in fasting blood glucose and body mass index with diagnosis of pancreatic cancer. Am J Gastroenterol. 2009;104:2318–2325
   PubMed Web of Science ®Google Scholar
• . Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology. 2009;137(2):482–488
   PubMed Web of Science ®Google Scholar
• . Pannala R. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology. 2008;134(4):981–987
   PubMed Web of Science ®Google Scholar
• . Ben Q, Xu M, Ning X,. Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. Eur J Cancer. 2011;47(13):1928–1937
   PubMed Web of Science ®Google Scholar
• . Elena JW, Steplowski E, Yu K,. Diabetes and risk of pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Cancer Causes Control. 2013;24(1):13–25
   PubMed Web of Science ®Google Scholar
• . Basso D, Greco E, Fogar P,. Pancreatic cancer-associated diabetes mellitus: An open field for proteomic applications. Clinica Chimica Acta. 2005;357:184–189
   PubMed Web of Science ®Google Scholar
• . Ogino S, Shima K, Nosho K,. A cohort study of p27 localization in colon cancer, body mass index, and patient survival. Cancer Epidemiol Biomarkers Prev. 2009;18(6):1849–1858
   Google Scholar
• . Centers for Disease Control. Overweight and obesity: adult obesity facts. http://www.cdc.gov/obesity/data/adult.html. Accessed May 7, 2014
   Google Scholar
• . Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst. 2005;97(22):1679–1687
   PubMed Web of Science ®Google Scholar
• . Deng L, Gui Z, Zhao L, Wang J, Shen L. Diabetes mellitus and the incidence of colorectal cancer: an updated systematic review and meta-analysis. Dig Dis Sci. 2012;57:1576–1585
   PubMed Web of Science ®Google Scholar
• . Yang YX, Hennessy S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology. 2004;127(4):1044–1050
   PubMed Web of Science ®Google Scholar
• . Meyerhardt JA, Catalano PJ, Haller DG,. Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol. 2003;21(3):433–440
   PubMed Web of Science ®Google Scholar
• . Singh S, Singh H, Singh PP, Murad MH, Limburg PJ. Antidiabetic medications and the risk of colorectal cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prevent. 2013;22(12):2258–2268
   PubMed Web of Science ®Google Scholar
• . Pisani P. Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Arch Physiol Biochem. 2008;114(1):63–70
   PubMedGoogle Scholar
• . Belfiore A, Malaguarnera R. Insulin receptor and cancer. Endocrine-Related Cancer. 2011;18(4):R125–R147
   PubMed Web of Science ®Google Scholar
• . Westley RL, May FE. A twenty-first century cancer epidemic caused by obesity: the involvement of insulin, diabetes, and insulin-like growth factors. Int J Endocrinol. 2013;632461
   Google Scholar
• . Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer. 2012;12(3):159–169
   PubMed Web of Science ®Google Scholar
• . LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett. 2003;195(2):127–137
   PubMed Web of Science ®Google Scholar
• . Durai R, Yang W, Gupta S, Seifalian A, Winslet M. The role of the insulin-like growth factor system in colorectal cancer: review of current knowledge. Int J Colorectal Dis. 2005;20(3):203–220
   Google Scholar
• . Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst. 2002;94(13):972–980
   PubMedGoogle Scholar
• . Samaras TT, Elrick H, Storms LH. Birthweight, rapid growth, cancer, and longevity: a review. J Natl Med Assoc. 2003;95(12):1170–1183
   PubMed Web of Science ®Google Scholar
• . Jing M, Pollak MN, Giovannucci E,. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor and IGF-binding protein-3. J Natl Cancer Inst. 1999;91(7):620–625
   Google Scholar
• . Durai R, Yang W, Gupta S, Seifalian A, Winslet M. The role of the insulin-like growth factor system in colorectal cancer: review of current knowledge. Int J Colorectal Dis. 2005;20(3):203–220
   Google Scholar
• . Doi T, Muro K, Yoshino T,. Phase I pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer. Cancer Chemother Pharmacol. 2013;72(3):643–652
   Google Scholar
• . Tolcher AW, Sarantopoulos J, Patnaik A,. Phase I pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol. 2009;27(34):5800–5807
   PubMed Web of Science ®Google Scholar
• . Yan SD, Schmidt AM, Anderson GM,. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem. 1994;269(13):9889
   PubMed Web of Science ®Google Scholar
• . Fuentes MK, Nigavekar SS, Arumugam T,. RAGE activation by S100P in colon cancer stimulates growth, migration, and cell signaling pathways. Dis Colon Rectum. 2007;50(8):1230–1240
   PubMed Web of Science ®Google Scholar
• . Boye K, Grotterod I, Aasheim HC, Hovig E, Maelandsmo GM. Activation of NFkappaB by extracellular S100A4: analysis of signal transduction mechanisms and identification of target genes. Int J Cancer. 2008;123:1301–1310
   PubMed Web of Science ®Google Scholar
• . Gebhardt C, Riehl A, Durchdewald M,. RAGE signaling sustains inflammation and promotes tumor development. J Exp Med. 2008;205(2):275–285
   Google Scholar
• . Arumugam T, Simeone D, Van Golen K, Logsdon C. S100P promotes pancreatic cancer growth, survival, and invasion. Clin Cancer Res. 2005;11(15):5356–5364
   PubMed Web of Science ®Google Scholar
• . Kang R, Tang D, Schapiro NE,. The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Different. 2010;17(4):666–676
   PubMed Web of Science ®Google Scholar
• . Liang H, Zhong Y, Zhou S, Peng L. Knockdown of RAGE expression inhibits colorectal cancer cell invasion and suppresses angiogenesis in vitro and in vivo. Cancer Lett. 2011;313(1):91–98
   PubMed Web of Science ®Google Scholar
• . Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, Bost F. Metformin in cancer therapy: a new perspective for an old antidiabetic drug. Mol Cancer Ther. 2010;9(5):1092–1099
   PubMed Web of Science ®Google Scholar
• . Bowker S, Majumadar S, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006;29:254–258
   PubMed Web of Science ®Google Scholar
• . Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD. New users of metformin are at low risk of incident cancer. Diabetes Care. 2009;32(9):1620–1625
   PubMed Web of Science ®Google Scholar
• . Currie CJ, Poole CD, Gale AM. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009;52:1745–1754
   Google Scholar
• . Soranna D, Scotti L, Zambon A,. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist. 2012;17(6):813–822
   PubMed Web of Science ®Google Scholar
• . Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated with metformin. PloS One. 2012;7(3):e33411
   PubMed Web of Science ®Google Scholar
• . Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330:1304–1305
   PubMed Web of Science ®Google Scholar
• . Will MA, Palaniappan M, Peegel H, Kayampilly P, Menon KMJ. Metformin: direct inhibition of rat ovarian theca-interstitial cell proliferation. Fertil Steril. 2012;98(1):207–214
   Google Scholar
• . Feng YH, Velazquez-Torres G, Gully C, Chen J, Lee MH, Yeung SC. The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth. J Cell Mol Med. 2011;15(4):825–836
   PubMed Web of Science ®Google Scholar
• . Vazquez-Martin A, Oliveras-Ferraros C, Del Barco S, Martin-Castillo B, Menendez JA. mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb(R)). Clin Transl Oncol. 2009;11(7):455–459
   Google Scholar
• . Bhalla K, Hwang BJ, Dewi RE,. Metformin prevents liver tumori-genesis by inhibiting pathways driving hepatic lipogenesis. Cancer Prev Res. 2012;5(4):544–552
   PubMed Web of Science ®Google Scholar
• . Rumi MA, Ishihara S, Kadowaki Y,. Peroxisome proliferator-activated receptor gamma-dependent and -independent growth inhibition of gastrointestinal tumour cells. Genes Cells. 2004;9(11):1113–1123
   Google Scholar
• . Eibl G, Wente MN, Reber HA, Hines OJ. Peroxisome proliferator-activated receptor gamma induces pancreatic cancer cell apoptosis. Biochem Biophys Res Commun. 2001;287(2):522–529
   Google Scholar
• . Schaefer KL, Wada K, Takahashi H,. Peroxisome proliferator-activated receptor gamma inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells. Cancer Res. 2005;65(6):2251–2259
   Google Scholar
• . Yu J, Qiao L, Zimmermann L,. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo. Hepatology. 2006;43(1):134–143
   Google Scholar
• . Mueller E, Smith M, Sarraf P,. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci U S A. 2000;97(20):10990–10995
   PubMed Web of Science ®Google Scholar
• . Panigrahy D, Singer S, Shen LQ,. PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest. 2002;110(7):923–932
   PubMed Web of Science ®Google Scholar
• . Koga H, Sakisaka S, Harada M,. Involvement of p21(WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines. Hepatology. 2001;33(5):1087–1097
   Google Scholar
• . Borbath I, Leclercq I, Moulin P, Sempoux C, Horsmans Y. The PPARgamma agonist pioglitazone inhibits early neoplastic occurrence in the rat liver. Eur J Cancer. 2007;43(11):1755–1763
   Google Scholar
• . Li MY, Deng H, Zhao JM, Dai D, Tan XY. PPARgamma pathway activation results in apoptosis and COX-2 inhibition in HepG2 cells. World J Gastroenterol. 2003;9(6):1220–1226
   Google Scholar
• . Boettcher E, Csako G, Pucino F, Wesley R, Loomba R. Meta-analysis: pioglitazone improves liver histology and fibrosis in patient with nonalcoholic steatohepatitis. Aliment Pharmacol Ther. 2012;35(1):66–75
   PubMed Web of Science ®Google Scholar
• . Sanyal AJ, Chalasani N, Kowdley KV,. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675–1685
   PubMed Web of Science ®Google Scholar
• . Vigneri R, Squatrito S, Sciacca L. Insulin and its analogs: actions via insulin and IGF receptors. Acta Diabetol. 2010;47(4):271–278
   PubMed Web of Science ®Google Scholar
• . Hemkens LG, Grouven U, Bender R,. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. 2009;52:1732–1744
   PubMed Web of Science ®Google Scholar
• . McFarland M, Cripps R. Diabetes mellitus and increased risk of cancer: focus on metformin and the insulin analogs. Pharmacotherapy. 2010;30(11):1159–1178
   Google Scholar
• . Wang L, Cai S, Teng Z, Zhao X, Chen X, Bai X. Insulin therapy contributes to the increased risk of colorectal cancer in diabetes patients: a meta-analysis. Diagn Pathol. 2013;8(1):180
   Google Scholar
• . Handelsman Y, LeRoith D, Bloomgarden Z,. Diabetes and cancer—an AACE/ACE consensus statement. Endocr Pract. 2013;19(4):675–693
   Web of Science ®Google Scholar